P3 Health Partners provides preliminary 2025 guidance; proposes $30M note from largest shareholder

P3 Health Partners Inc.

Preliminary 2025 revenue guidance of $1.35B-$1.5B; Adjusted EBITDA of $(35)M to $5M.
At-risk members guidance of 108k-118k for FY2025.
Proposed $30M unsecured promissory note and warrants from largest shareholder, terms similar to Dec 2024 financing.
CEO states $130M+ EBITDA growth initiatives on track; targeting profitability in 2025.
Full 2025 guidance to be issued with Q4 2024 earnings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.